Literature DB >> 26725959

Impact of the use of an endorectal balloon on rectal dosimetry during stereotactic body radiation therapy for localized prostate cancer.

Andrew T Wong1, David Schreiber2, Manuj Agarwal2, Aleksey Polubarov3, David Schwartz2.   

Abstract

PURPOSE: Endorectal balloons may be of benefit during stereotactic body radiation therapy of the prostate to limit intrafraction prostatic motion and potentially minimize rectal toxicity. We evaluated the effect of the endorectal balloon (ERB) on rectal dosimetry, specifically the absolute volume of rectum receiving high dose. METHODS AND MATERIALS: Eleven patients with localized prostate cancer underwent stereotactic body radiation therapy planning with computed tomography simulation with and without a RadiaDyne ERB inflated with 60 mL of water. Prescription dose was 3625 cGy in 5 fractions of 725 cGy. The V3600 (volume receiving 3600 cGy), V3440 (volume receiving 3440 cGy), and volume receiving 50% of the prescription dose were calculated for both the rectum and rectal wall. Repeat plans were generated using smaller planning target volume margins (reduced to 1 mm from 3 mm posteriorly) and after virtually replacing the water-filled ERB with air equivalent density. Comparisons were made using the Wilcoxon signed-rank test.
RESULTS: The rectal V3600 and V3440 were significantly lower without ERB than with water-filled ERB using standard 3-mm posterior margin (P = .003 for both V3600/V3440), water-filled ERB using reduced 1-mm posterior margin (P = .016 and .003), or air-filled ERB (P = .003 and .004). Regarding the rectal wall, V3600 and V3440 were also significantly lower without ERB than with any ERB, except when using the water-filled ERB with reduced posterior margin (P = .328). The volumes of rectum and rectal wall receiving lower dose (volume receiving 50% of the prescription dose) were not significantly greater without the ERB.
CONCLUSION: We found an increase in the volume of rectum and rectal wall receiving high dose radiation utilizing an ERB. Consideration in using an ERB should account for potential increased rectal dose and subsequent toxicity.
Copyright © 2016 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26725959     DOI: 10.1016/j.prro.2015.10.019

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  4 in total

1.  Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?

Authors:  Angèle Dubouloz; Michel Rouzaud; Lev Tsvang; Wilko Verbakel; Mikko Björkqvist; Nadine Linthout; Joana Lencart; Juan María Pérez-Moreno; Zeynep Ozen; Lluís Escude; Thomas Zilli; Raymond Miralbell
Journal:  Radiat Oncol       Date:  2018-06-19       Impact factor: 3.481

2.  Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer.

Authors:  Hong F Xiang; Hsiao-Ming Lu; Jason A Efstathiou; Anthony L Zietman; Ricardo De Armas; Kathryn Harris; B Nicolas Bloch; Muhammad Mustafa Qureshi; Sean Keohan; Ariel E Hirsch
Journal:  J Appl Clin Med Phys       Date:  2017-04-13       Impact factor: 2.102

3.  Impact of intrafraction changes in delivered dose of the day for prostate cancer patients treated with stereotactic body radiotherapy via MR-Linac.

Authors:  Jennifer Dang; Vickie Kong; Winnie Li; Inmaculada Navarro; Jeff D Winter; Victor Malkov; Alejandro Berlin; Charles Catton; Jerusha Padayachee; Srinivas Raman; Padraig Warde; Peter Chung
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2022-08-27

4.  Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.

Authors:  Darren M C Poon; Daisy Lam; Kenneth C W Wong; Cheuk-Man Chu; Michael Cheung; Frankie Mo; Joyce Suen; Chi-Fai Ng; Anthony T C Chan
Journal:  Curr Oncol       Date:  2021-12-22       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.